Immunovant Inc. Common Stock vs Kenvue Inc. Common Stock — how do they compare? Immunovant Inc. Common Stock trades at $30.41 (market cap $6.25B), while Kenvue Inc. Common Stock trades at $17.74 (market cap $34.06B). The key difference: Kenvue Inc. Common Stock is far larger — about 5.4× Immunovant Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IMVT | KVUE | |
|---|---|---|
Market Cap | $6.25B | $34.06B |
Volume | 1,755,411 | 23,267,228 |
Sector | Health | Consumer Staples |
52-Week High | $44.96 | $19.83 |
52-Week Low | $17.03 | $14.11 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $5.35B | $41.56B |
Dividend Yield | — | 4.74% |
Trailing returns across standard periods
Latest headlines on both assets
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →